U.S. Department of Health and Human Services Office of Disease Prevention and Health Promotion

Prevent an increase in the proportion of nontyphoidal Salmonella infections that are resistant to multiple drug classes — FS‑05 Data Methodology and Measurement

On this page:  About the National Data  |  Methodology  |  History

About the National Data

Data

Data Source:  National Antimicrobial Resistance Monitoring System for Enteric Bacteria (NARMS), CDC/NCEZID

Baseline: 9.3 percent of nontyphoidal Salmonella infections in humans were resistant to 3 or more drug classes in 2016-18

Target: 9.3 percent

Numerator
Number of nontyphoidal Salmonella isolates from humans resistant to 3 or more drug classes.
Denominator
Number of nontyphoidal Salmonella isolates from humans tested for resistance to 3 or more drug classes.
Target-setting method
Maintain the baseline
Target-setting method justification
Maintaining the baseline is the preferred target because, by reducing the overall incidence of infections and limiting the prevalence of resistance (maintaining the current level), a reduction in the incidence of antimicrobial resistant infections can be achieved.

Methodology

Methodology notes

Public health laboratories in 50 state and 4 local health departments forward every 20th nontyphoidal Salmonella isolate that they receive from clinical laboratories to NARMS at CDC. CDC scientists test isolates for susceptibility to antimicrobial agents representing nine or more drug classes using a broth microdilution method and interpret results using criteria from the Clinical and Laboratory Standards Institute (CLSI) when available.

History

Comparable HP2020 objective
Modified, which includes core objectives that are continuing from Healthy People 2020 but underwent a change in measurement.
Changes between HP2020 and HP2030
This objective differs from Healthy People 2020 objective FS-3.5 in that objective FS-3.5 defined quinolone class resistance as resistant or intermediate to ciprofloxacin, while this objective defines resistance as resistant or intermediate to ciprofloxacin or resistant to nalidixic acid.
Revision History
Revised. 

In 2023, the baseline and target were changed from 10.6 in 2015-2017 to 9.3 in 2016-2018 to align the baseline year range with the other Food Safety Topic Area objectives.